Enhanced levels of platelet/granulocyte aggregates (PGAs) are found in patients suffering from many different inflammatory vascular diseases, and their formation in animal models of vascular disease is associated with increased thromboinflammation and worsened outcomes. The complement system, a part of the innate immune system, influences PGA formation, but the mechanisms for its effects are unknown. In this study, we have defined complement-mediated mechanisms that enhance PGA formation in human whole blood stimulated with thrombin receptor-activating peptide (TRAP) using ex vivo flow cytometry assays. We demonstrate that physiological properdin, a positive regulator of complement alternative pathway activity, increases PGA formation when added to TRAP-stimulated blood. All physiological properdin forms increase PGA formation, but properdin tetramers are the most efficient at increasing complement activity and PGA formation. Inhibition of endogenous properdin, either circulating in the blood or produced locally by leukocytes, impairs TRAP-mediated PGA formation to the same level as specific inhibition of either the alternative or classical pathway. Additionally, blocking the interaction of C5a with its cellular receptor prevents properdinmediated increases in PGA formation. Adding either properdin tetramers or C5a to whole blood increases CD11b expression on granulocytes, and this increase is prevented by blockade of the C5a-C5a receptor axis. Finally, we demonstrate that the effects of properdin on PGA formation are tightly regulated by Factor H. Cumulatively, our data indicate that properdin enhances PGA formation via increased production of C5a, and that inhibition of properdin function has therapeutic potential to limit thromboinflammation in diseases characterized by increased PGA formation.
P latelets are critical for vascular hemostasis and repair in response to blood vessel damage (1) . Platelets also help initiate inflammatory responses that induce endothelial regeneration and vessel protection from potential invasion by microorganisms by binding and recruiting leukocytes to sites of vascular damage (1) (2) (3) (4) . Leukocytes not only promote inflammation, but they have a dynamic role in the regulation of thrombosis. Tissue factor expressed on leukocyte surfaces or leukocyte-derived microparticles increases thrombus formation (5-8), whereas leukocytes limit thrombus formation by directly phagocytosing activated platelets, decreasing local levels of ADP, and preventing fibrinogen binding to platelets (9) . Platelets and leukocytes interact to form stable platelet/leukocyte aggregates (PLAs) (10) , which involves an ordered series of events where P-selectin on activated platelets binds to P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes. This stimulates the upregulation and activation of complement receptor 3 (CR3; CD11b/CD18; Mac-1) on leukocytes, which then binds multiple ligands on platelets to form stable aggregates (11) (12) (13) (14) . Excessive PLA formation increases tissue factor expression, secretion of proinflammatory cytokines and chemokines, production of reactive oxygen species, secretion of damaging proteases, and upregulation of adhesion molecules on leukocytes (11) (12) (13) . Increased levels of circulating PLAs are found in patients suffering from many inflammatory diseases, including cardiovascular, myeloproliferative, and inflammatory bowel diseases (15) (16) (17) (18) (19) (20) , and inhibiting PLA formation (by inhibiting P-selectin or CD11b) reduces pathology and improves outcomes in various vascular injury animal models (8, (21) (22) (23) (24) . Understanding mechanisms by which PLA formation is regulated is imperative to elucidate how PLAs can increase to levels that result in pathologic thromboinflammation and to identify potential therapeutic targets.
The complement system links the innate and adaptive immune systems and helps orchestrate inflammatory reactions. Complement activity can initiate by three distinct pathways (classical, lectin, and alternative) that converge at the cleavage of the central molecule, C3, to C3b and C3a. C3b binds covalently to exposed hydroxyl and amino groups on cell surfaces, enabling the formation of C3/C5 convertases that amplify complement activity and lead to activation of terminal complement components to produce the anaphylatoxin C5a and the membrane attack complex (MAC; C5b-9) (25) . Although all three pathways recognize distinct molecular patterns on cell surfaces to activate, the alternative pathway (AP) mainly initiates spontaneously in the fluid phase (25, 26) . Properdin, the only known positive complement regulatory molecule, stabilizes the AP convertases, increasing their activity 5-to 10-fold (26) . The AP amplifies on any surface on which C3b is bound, including C3b originally deposited by the lectin or classical pathways (CP); thus it is an essential amplification loop for all complement activity. All pathways must be tightly regulated to prevent unwanted tissue damage (25) . Factor H (FH) is a key regulator of the AP (27) .
Physiological properdin circulates in plasma at 4-25 mg/ml as dimers (P 2 ), trimers (P 3 ), and tetramers (P 4 ) of head-to-tail associations of monomeric subunits; however, repeated freeze/thaw cycles can form higher order nonphysiological aggregates (P n ) that bind nonspecifically to surfaces and consume complement in solution (28) (29) (30) (31) . Properdin is primarily produced by leukocytes, including neutrophils, which secrete properdin in response to proinflammatory stimuli, leading to higher concentrations at inflammatory locations (26, 32, 33) . AP activation on activated platelets leads to terminal complement activation, generating MAC (31), which enhances platelet activation (34, 35) , and C5a. C5a contributes to formation of platelet/granulocyte aggregates (PGAs) in human whole blood stimulated with thrombin receptoractivating peptide (TRAP) (14, 36) ; however the complement pathways involved, as well as the role of physiological properdin in this process, are unknown. In this study, we have elucidated a critical role for physiological properdin in amplifying AP and CP activity at the platelet/granulocyte interface to increase PGA formation via C5a production, with resulting C5a-mediated CD11b upregulation on granulocytes, all of which is tightly controlled by FH.
Materials and Methods

Buffers
Modified HEPES/Tyrode's (HT) buffer (137 mM NaCl, 2.8 mM KCl, 1 mM MgCl 2 , 12 mM NaHCO 3 , 0.4 mM Na 2 HPO 4 , 10 mM HEPES, 0.35% BSA, 5.5 mM glucose [pH 7.4]) and PBS (10 mM NaH 2 PO 4 , 145mM NaCl [pH 7.4]) were used as buffers.
Detection Abs
Murine mAbs (all IgG1) included anti-human CD42b-allophycocyanin (BioLegend), anti-human CD45-PE (BioLegend), anti-human/mouse C3/ C3b/iC3b-FITC (Cedarlane Laboratories), and anti-human CD11b-PerCP/ Cy5.5 (BioLegend). IgG1 isotype controls included allophycocyanin-and PerCP/Cy5.5-labeled (BioLegend), PE-labeled (Chemicon), and FITClabeled (Cedarlane Laboratories) Abs.
Complement modulators
To inhibit convertase-mediated C3 activation, either the originally described C3 inhibitor compstatin (I[CVVQDWGHHRC]T-NH 2; Tocris Bioscience) (37) or the ∼1000-fold more potent analog Cp20 (Ac-I[CV-1MeW-QDWSar-AHRC]mI-NH 2; prepared by solid-phase peptide synthesis) (38) was used. At concentrations in large excess of C3 as used in our assays (50 mM final), both compstatin analogs were equally effective at inhibiting TRAPmediated PGA formation and C3 fragment deposition on granulocytes (Supplemental Fig. 1 ). Samples receiving either compstatin analog were designated "Comp." PMX53 (39), a recombinant protein consisting of domains 19-20 of FH (rH19-20) (40) , and anti-Factor B mAb no. 1379 (41) were produced as previously described. We generated, purified, and characterized three mouse IgG1k anti-properdin mAbs: 3A3E1, 6E11A4, and 1G6D2 (H. Emch, N. Galwankar, S. Pathan, A.Z. Blatt, and V.P. Ferreira, manuscript in preparation). 1G6D2, which does not inhibit properdin function, was used as both a negative inhibition control and isotype control. SALO, a specific CP inhibitor, was generated as previously described (42) . C5a was purchased from Complement Technologies.
Purification of properdin and separation of physiological forms
Purification of properdin from normal human plasma was carried out as previously described (30) . Physiological polymeric forms of properdin (P 2 , P 3 , P 4 ) were separated from P n s by gel filtration chromatography. Briefly, pure properdin (5 mg) was loaded onto a Phenomenex BioSep-Sec-S4000 column (600 3 7.8 mm) with a guard column (75 3 7.8 mm) and eluted at a 0.5 ml/min flow rate in PBS. Purified, physiological forms of properdin were stored at 4˚C and used within 2 wk of separation (28, 30) .
Measurement of TRAP-mediated PGA formation, C3 fragment deposition, and CD11b expression
Human whole blood was collected via venipuncture from healthy donors. The Institutional Review Board from the University of Toledo College of Medicine and Life Sciences approved the protocols, and written informed consent was obtained from all donors, in accordance with the Declaration of Helsinki. Blood was drawn into BD Vacutainer tubes containing 50 mg/ml lepirudin (Refludan; Bayer or Celgene, donation from Dr. Sanjay Ram). Blood (20 ml) was immediately gently mixed with 60 ml total of modified HT buffer plus reagents (TRAP [Bachem] with or without properdin, complement modulators, and/or rH19-20), previously added to tubes at room temperature. TRAP was used at a final concentration of 20 mM, unless otherwise indicated. Complement modulators were used at the final concentrations indicated in the figure legends. Compstatin (50 mM final) was used as a positive control for complete complement inhibition. A sample that was not activated with TRAP, but received compstatin immediately after blood collection (designated as nonactivated plus compstatin [NA+Comp]) served as the baseline control for C3 fragment deposition and CD11b expression. The blood plus reagents mixture was incubated at 37˚C for 15 min. The reaction was stopped using 800 ml RBC lysis/fixation solution (BioLegend). The samples were then washed with modified HT buffer and stained with detection Abs for 15 min at room temperature. At least 10,000 events (granulocytes and monocytes) were acquired using a Becton Dickinson FACSCalibur flow cytometer, and the data were analyzed using FlowJo 7.6 software (Tree Star). Granulocytes were gated based on CD45-associated fluorescence and side scatter, and the percentages of gated granulocytes positive for CD42b fluorescence, as well as the C3-and CD11b-associated geometric mean fluorescence intensities on gated granulocytes, were determined.
Analysis of C5a levels in reaction supernatants
Whole-blood experiments were set up as described above, in triplicate. Following the 37˚C incubation (blood plus reagents), one set of tubes was immediately centrifuged at 300 3 g for 10 min at 4˚C. The supernatant was then centrifuged at 13,000 3 g for 5 min at 4˚C and immediately stored at 280˚C until use. Supernatants were diluted 1:10 and analyzed using a C5a ELISA kit (Abcam), following the manufacturer's instructions. The remaining two sets of tubes were processed as described above to determine PGA formation, C3 fragment deposition, and CD11b expression.
Statistical analysis
The data were analyzed with GraphPad Prism 6.0 software. Cumulative raw data were analyzed by repeated measures ANOVA with a Dunnett posttest, using the Geisser-Greenhouse correction, to compare groups to TRAP alone. Individual experiments were analyzed by one-way ANOVA with either a Dunnett or Tukey posttest, depending on the experiment. Statistical tests are indicated in the figure legends.
Results
Physiological properdin forms increase PGA formation
Properdin circulates as P 2 , P 3 , and P 4 in an approximate 1:2:1 ratio (28). Repeated freeze-thaw cycles cause purified properdin to form P n s with the abnormal ability to activate complement in solution (28, 29) as well as bind nonspecifically to surfaces (30, 43) , including NA platelets (31) . In a study conducted by Ruef et al. (44) , purified properdin significantly increased PLA formation in citrateanticoagulated human whole blood. To accurately assess the function of purified properdin in human whole blood, it is essential to separate P n s from P 2 -P 4 s and to avoid certain anticoagulants, such as citrate, that dampen complement activation and PLA formation (45, 46) . In the present study, we separated P 2 -P 4 s from P n s by size exclusion chromatography to determine the effects of physiological properdin on PGA formation. In our assays, lepirudin, a direct thrombin inhibitor without any complement inhibitory properties (47) , was used as the anticoagulant, and human whole blood was stimulated with TRAP, an agonist that directly stimulates thrombin receptors (48) .
Fig . 1A shows the gating strategy used to identify granulocyte populations (49) . Fig. 1B and 1C are dot plots showing an increase in the percentage of granulocytes with associated CD42b fluorescence (i.e., platelets) upon addition of 25 mg/ml physiological properdin forms (P 2 -P 4 ) in a 1:2:1 ratio to TRAP-stimulated whole blood. Fig. 1D shows that the addition of P 2 -P 4 leads to an ∼2-fold increase in PGA formation compared with TRAP-stimulated whole blood without added properdin. The effect of properdin on TRAPmediated PGA formation is dose-dependent, as properdin caused a significant increase in PGA formation at concentrations as low as 2 mg/ml and reached its maximal effects by 10 mg/ml (Fig. 1E) .
To determine whether the physiological properdin forms had differential effects on PGA formation, each form was individually added to whole blood stimulated with TRAP (Fig. 1F, 1G) . A lower dose of TRAP (10 mM) was used in these experiments to increase the sensitivity of detecting properdin-mediated effects on PGA formation. Fig. 1F shows the representative data from one of four independent experiments conducted with different donors' blood. The effects of properdin were dose-dependent, and P 4 s increased PGA formation to a greater extent than P 2 s and P 3 s, requiring lower concentrations to achieve maximal effects. P 3 s caused greater increases in PGA formation than P 2 s at each concentration tested. There was considerable interindividual variation in the maximal effects of each form on PGA formation (P 4 s, 2.5-to 14-fold; P 3 s, 2.5-to 11-fold; P 2 s, 2-to 5-fold increases in PGA over TRAP alone), but for each individual, P 4 s always had the greatest effect.
C3 fragments deposited on the granulocytes serve as a marker of the degree of complement activation induced or enhanced by each properdin form. Fig. 1G shows that P 4 s were the most efficient at increasing, in a dose-dependent manner, C3 fragment deposition (by ∼3-fold) on granulocytes in TRAP-stimulated whole blood. P 2 s and P 3 s increased C3 fragment deposition on granulocytes to Representative bar graph of (B) and (C). **p , 0.01. (E) Dose curve of effects of P 2 -P 4 on TRAP-mediated PGA formation. (F and G) Effect of different physiological properdin forms on PGA formation and C3 fragment deposition on granulocytes within the same experiment. Lepirudin anticoagulated whole blood was incubated with a submaximal dose of TRAP (10 mM) and increasing concentrations of individual properdin forms (P 2 , P 3 , P 4 ; 0-50 mg/ml). Samples were processed as described in Materials and Methods. The p values were ,0.05 as compared with TRAP alone (0 mg/ml properdin form), unless indicated in red. Maximal effects of properdin forms on C3 fragment deposition varied depending on the donor (P 4 s, 1.5-to 3-fold; P 2 s and P 3 s, 1.2-to 2-fold increases over TRAP alone); one donor shown in (G). (A-G) All experiments shown are representative of at least four independent experiments and are shown as mean and SD of duplicate observations. The data were analyzed by one-way ANOVA with a Dunnett multiple comparison test against TRAP alone. GMFI, geometric mean fluorescence intensity.
approximately the same level, but to a significantly lesser extent than P 4 s, even when used at concentrations 2-fold higher than the maximal P 4 dose (Fig. 1G) . Collectively, the data indicate that all physiological properdin forms increase PGA formation, but P 4 s cause the greatest increases and account for most C3 fragments deposited on the granulocytes in TRAP-stimulated whole blood.
Inhibition of endogenous properdin reduces TRAP-induced PGA formation
Because properdin is produced locally by leukocytes upon stimulation, its concentration in inflammatory microenvironments could be significantly higher than its plasma concentration of 4-25 mg/ml (26) . Therefore, we sought to determine whether endogenous properdin (produced locally by leukocytes or already circulating in the plasma) modulates the basal level of TRAP-mediated PGA formation. We incubated TRAP-stimulated whole blood with three different anti-properdin mAbs that we recently produced and characterized: 3A3E1, 6E11A4, and 1G6D2 (H. Emch et al., manuscript in preparation). 3A3E1 and 6E11A4 inhibit AP-mediated lysis of rabbit erythrocytes by preventing properdin from binding to C3b. 1G6D2 recognizes properdin, is the same isotype as the inhibitory Abs (IgG1), and does not inhibit AP-mediated lysis of rabbit erythrocytes. Thus, 1G6D2 was used as a negative control for assessing properdin function. Fig. 2A shows that the inhibitory Abs, 3A3E1 and 6E11A4, significantly inhibited PGA formation relative to TRAP alone, whereas 1G6D2 did not. Fig. 2B shows the data for each donor graphed relative to the level of PGA formation induced by TRAP alone in that particular donor (such that TRAP alone = 1 for each donor). The data indicate that the addition of 3A3E1 and 6E11A4 reduced PGA formation by ∼50% regardless of the level of PGA formation induced by TRAP alone in each donor's blood (Fig. 2B) . A low level of C3 fragment deposition, most likely due to complement activation on granulocytes during processing (before the addition of compstatin), was detected on NA+Comp groups (Fig. 2C, 2D ; isotype control for C3 fragment detection ∼0.3-0.6 relative to TRAP; not shown). C3 fragment deposition trended toward an increase on TRAP versus NA+Comp groups (Fig. 2C , p = 0.08), whereas 3A3E1 and 6E11A4 significantly reduced C3 fragment deposition by ∼30% as compared with TRAP alone (Fig. 2C, 2D ). C3-covered microparticles released from granulocytes during D) were determined in the same experiment, as described in Materials and Methods. The mean for each group, assessed in duplicate, is graphed in (A) and (C), whereas (B) and (D) represent the mean for each group graphed relative to the mean of TRAP alone (assigned a value of 1) for each independent experiment, and the SD of each group is shown. The data were analyzed by repeated measures ANOVA with a Dunnett multiple comparison test against TRAP alone. (A and C) p , 0.05 compared with TRAP alone unless indicated as nonsignificant. GMFI, geometric mean fluorescence intensity.
FIGURE 5. P 4 s increase PGA formation via C5a-mediated enhancement of CD11b expression. Lepirudin anticoagulated whole blood was incubated with TRAP alone (10 mM) or in combination with P 4 s (5 mg/ml) and anticomplement reagents (anti-properdin, 100 mg/ml; PMX53, 16.7 mM; Comp, 50 mM). PGA formation (A), C5a in supernatants (B), and CD11b expression (C) were determined as described in Materials and Methods. Results shown in (A) and (C) are representative of one of five independent experiments carried out with different human volunteer blood samples, and in two of these five experiments C5a was also determined [one representative experiment shown in (B)]. Two additional C5a ELISAs were carried out using supernatants harvested from experiments carried out under identical conditions, but that did not include duplicate samples for flow cytometry analysis. In the five independent experiments, effects of P 4 s on PGA formation varied from 2.5-to 14-fold increases over TRAP alone, depending on the donor (variation not shown). Results are shown as mean and SD of duplicate observations. The data were analyzed by one-way ANOVA with a Dunnett multiple comparison test against TRAP+P 4 .
The p values were ,0.001 compared with TRAP+P 4 unless indicated as nonsignificant. GMFI, geometric mean fluorescence intensity.
PGA formation (50) could reduce the total amount of detectable C3 fragments on granulocytes. This, combined with the inhibition of AP activity, may explain why TRAP plus 3A3E1 and 6E11A4 groups had lower C3 fragment levels than did the NA+Comp control. 1G6D2 did not affect C3 fragment deposition (Fig. 2C,  2D) ; thus inhibition of endogenous properdin function significantly limits complement activity and PGA formation in TRAPstimulated whole blood.
AP and CP activation contribute to TRAP-mediated PGA formation
Platelets can activate both the CP and AP on their surface (31, 51, 52) and secrete chondroitin sulfate, which activates the CP in the fluid phase (36, 53) . Isolated neutrophils also activate the AP on their surface (32) . Because the AP can amplify complement using C3b originally deposited by the CP, we next determined whether the effects of properdin on PGA formation (Fig. 2) were due to AP activation alone or also due to amplification of CP activity.
Anti-Factor B no. 1379, an inhibitory mAb (41) , and SALO, a salivary protein produced by the sandfly Lutzomyia longipalpis (54-56) that specifically inhibits the CP (42), were used to determine the effects of AP and CP inhibition on TRAP-mediated PGA formation, respectively. Addition of either anti-Factor B no. 1379 or SALO to whole blood significantly impaired TRAPmediated PGA formation in each donor's blood by an average of ∼50% (Fig. 3A, 3B and 3C, 3D, respectively, and Fig. 4A, 4B ), as well as C3 fragment deposition (Fig. 4C, 4D ) in a mode similar to the anti-properdin monoclonals (Figs. 2, 4 ). These data, as well as the ability of the CP inhibitor to inhibit PGA formation and C3 fragment deposition to the same level as inhibiting all complement activity with compstatin (Fig. 4) , even when AP activity is intact, suggest that complement activity in TRAP-stimulated whole blood may be initiated by the CP and amplified by properdin-mediated AP convertase stabilization.
Properdin-mediated C5a generation enhances TRAP-mediated PGA formation via upregulation of CD11b on granulocytes
We next investigated the potential downstream effector molecules that could account for properdin's effects on PGA formation. PMX53, a peptide that blocks the interaction of C5a with its receptor (39) , was previously shown to impair TRAP-mediated PGA formation (14, 36) . We compared the effects of PMX53 to the effects of our other reagents in the same donor's blood to discern whether C5a and/or MAC generation influences PGA formation. All reagents except 1G6D2 significantly inhibited PGA formation to an average of ∼50% the level seen with TRAP alone (Fig. 4A,  4B ) and reduced C3 fragment deposition on granulocytes to a level similar to the NA+Comp control (Fig. 4C, 4D ). PMX53 and inhibition of properdin (3A3E1 and 6E11A4) had equivalent inhibitory effects on PGA formation as inhibiting all complement with compstatin ( Fig. 4A, 4B ), thus indicating that C5a is the key complement effector molecule for PGA formation in TRAP-stimulated blood and properdin is a key enhancer of C5a generation.
To confirm the role of properdin in generating C5a at the platelet/ granulocyte interface, we determined whether inhibition of C5a function with PMX53 could prevent P 4 -mediated increases in PGA formation. Fig. 5A shows that P 4 s increased PGA formation ∼7-fold over TRAP alone, and PMX53 completely inhibited P 4 -mediated enhancement of PGA formation. Compstatin, 3A3E1, and 6E11A4 had identical effects as PMX53. C5a levels in reaction supernatants were measured by ELISA (Fig. 5B) and displayed a pattern similar to that of PGA formation (Fig. 5A) , with PMX53 being the only exception, as expected, because it inhibits C5a function rather than generation.
Finally, we sought to determine a potential mechanism for the effects of properdin-mediated C5a generation on PGA formation. PMX53 was previously shown to inhibit CD11b (one of two chains that comprise CR3) upregulation on granulocytes in TRAPstimulated whole blood (36) . We measured CD11b expression on granulocytes in the presence of P 4 s and 3A3E1, 6E11A4, and PMX53, using 1G6D2 as a negative and IgG1k isotype control Ab. 3A3E1, 6E11A4, and PMX53 completely abrogated P 4 -mediated increases in CD11b expression, whereas 1G6D2 had a partial effect (Fig. 5C ), suggesting that properdin-mediated C5a generation enhances PGA formation via upregulation of CD11b on granulocytes. We next assessed the direct effect of C5a on PGA formation and CD11b expression. Although C5a had no effect on PGA formation on its own (Fig. 6A) , C5a caused an ∼1.5-fold increase in CD11b expression on granulocytes compared with the NA control (Fig. 6B) . C5a significantly increased PGA formation and CD11b expression on granulocytes in the presence of submaximal doses of TRAP (10 mM) by ∼1.5-fold (Fig. 6) . The effects of C5a on CD11b expression (either alone or with TRAP), as well as C5a enhancement of PGA formation in the presence of submaximal doses of TRAP, were all abrogated by PMX53 (Fig. 6 ). Taken together, our results indicate that properdin is key in promoting the generation of C5a at the platelet/granulocyte interface, which enhances PGA formation (in the presence of platelet agonists) by binding to C5a receptor 1 (C5aR1; CD88). This C5a/C5a receptor interaction results in upregulation of CR3 (CD11b/CD18) on granulocytes, contributing to aggregate stabilization. FIGURE 6 . C5a directly enhances TRAP-mediated PGA formation and CD11b expression. Lepirudin anticoagulated whole blood was incubated without or with TRAP (10mM) with or without C5a (210 nM) or C5a plus PMX53 (16.7 mM). Results are representative of five independent experiments in which PGA formation (A) and CD11b (B) expression on granulocytes were determined in the same experiment, as described in Materials and Methods. Results are shown as mean and SD of duplicate observations. The data were analyzed by one-way ANOVA with a Tukey multiple comparison test. **p , 0.01, ***p , 0.001. GMFI, geometric mean fluorescence intensity.
Properdin-mediated increases in PGA formation are tightly regulated by FH FH regulates the AP on cell surfaces and is the primary negative AP regulator in the fluid phase. It protects cell surfaces by recognizing and binding to the combination of C3b and polyanions via mainly its C-terminal domains, 19 and 20, while regulating complement with its N terminus (27, 40, 57) . A recombinant protein composed solely of FH domains 19 and 20, designated rH19-20, competitively inhibits FH cell surface interactions without affecting fluidphase regulation and simulates the pathophysiological mechanisms involved in the prothrombotic disease atypical hemolytic uremic syndrome (aHUS) (40, (58) (59) (60) . The contribution of FH to regulation of PGA formation is unknown.
The addition of rH19-20 to TRAP-stimulated whole blood increased PGA formation and C3 fragment deposition on granulocytes compared with TRAP alone (Fig. 7A, 7B) , indicating that FH cell surface protection is key in limiting TRAP-mediated PGA formation despite the presence of membrane-bound complement regulators on granulocytes and platelets. In NA blood, rH19-20 increased C3 fragment deposition on granulocytes and CD11b expression (Fig. 7B, 7C ), but did not affect the formation of PGA (Fig. 7A) . This is in agreement with the need for initial platelet activation for PGA formation (61) , and it suggests that complement effector molecules produced in the absence of FH cell surface protection do not activate platelets. Higher C3 fragment deposition and CD11b expression on granulocytes in NA versus TRAP-stimulated blood, in the presence of rH19-20, may be an indication that bound platelets mask detection of each marker or that TRAP stimulation leads to shedding of C3-and/or CD11b-coated microparticles under these conditions. To determine whether properdin activity could account for rH19-20-mediated increases in PGA formation, the TRAP-stimulated whole blood was incubated with rH19-20 in the presence of the anticomplement reagents (Fig. 7A, 7B) . 3A3E1, 6E11A4, anti-Factor B no. 1379, and compstatin significantly inhibited rH19-20-mediated increases in PGA formation and C3 fragment deposition to approximately the same level as NA blood, whereas 1G6D2 had no effect on PGA formation and a partial effect on C3 fragment deposition (Fig. 7A,  7B ). Partial effects of 1G6D2 on rH19-20-mediated C3 fragment deposition (Fig. 7B) and P 4 -mediated CD11b expression (Fig. 5C ) may occur due to steric hindrance of properdin function by Abproperdin complexes formed as a result of the high Ab concentrations used in our assays. Fig. 7C shows representative data indicating that inhibition of properdin, the AP, or all complement, reduces rH19-20-mediated increases in CD11b expression. These effects were observed in at least three of six experiments, except for 6E11A4, which significantly inhibited CD11b expression twice. The remaining experiments showed identical trends to Fig. 7C but did not reach statistical significance. Collectively, the data indicate that FH regulates properdin-mediated increases in AP activity and subsequent PGA formation by mechanisms including, but not necessarily limited to, increased CD11b expression in TRAP-stimulated whole blood. Fig. 8 shows a proposed model for the overall mechanisms of the effects of properdin on PGA formation.
Discussion
Given that platelets have important roles in hemostasis and in the immune response against microorganisms (2), it is essential to identify novel therapeutic targets to limit thrombosis and inflammation in the FIGURE 7. FH controls properdin-mediated PGA formation. Lepirudin anticoagulated whole blood was incubated with TRAP (10 mM) without or with the FH competitive inhibitor rH19-20 (20 mM) with or without anticomplement reagents (anti-properdin and antiFactor B no. 1379, 100 mg/ml; compstatin, 50 mM). A sample that did not receive TRAP (NA) with or without rH19-20 was also included for each experiment. PGA formation (A), C3 fragment deposition on granulocytes (B), and CD11b expression on granulocytes (C) were determined as described in Materials and Methods. Graphs are representative of six independent experiments in which (A)-(C) were determined in the same experiment, although statistical significance for CD11b expression only matched the representative figure in about three of six donors. Results are shown as mean and SD of duplicate observations. The data were analyzed by one-way ANOVA with a Tukey multiple comparison test. ***p , 0.001. GMFI, geometric mean fluorescence intensity.
vasculature without directly affecting platelet function. Granulocytes have both prothrombotic and proinflammatory potential; therefore finding ways to limit the recruitment and activation of granulocytes by platelets could lessen pathology caused by the innate immune response. Long-term blockade of all platelet/granulocyte interactions through the use of P-selectin/PSGL-1 or CR3 antagonists could potentially increase patient susceptibility to infections or even autoimmune diseases (62) (63) (64) . In this study, we have elucidated a role of properdin in influencing stable PGA formation, thus identifying properdin as a potential target for limiting leukocytemediated thromboinflammation without directly affecting platelet function or completely blocking platelet/granulocyte interactions in inflammatory vascular diseases.
The addition of physiological properdin enhanced PGA formation in TRAP-stimulated blood in a dose-dependent manner (Fig. 1 ). P 4 s were the most effective at increasing TRAP-mediated PGA formation and C3 fragment deposition on granulocytes (Figs. 1F,  1G , 5A). P 4 s also significantly increased C5a levels recovered in supernatants and CD11b expression on granulocytes (Fig. 5B,  5C ). The effectiveness of P 4 s is in agreement with their previously described high degree of native properdin activity (ability to stabilize the convertases, promoting AP activation) as compared with P 2 s and P 3 s (28). Additionally, weak fluid-phase complement activation by P 4 s (,7% that of aggregated/nonphysiological properdin) (28) may potentially contribute to C5a generation, thus enhancing PGA formation. Properdin is produced and secreted by many different leukocytes (26) , but it is unknown whether different leukocytes secrete properdin forms in the same physiological ratio found in plasma (28) . For instance, T cell-derived properdin was shown to be 100-fold more active than serum-derived properdin in an AP hemolytic assay (65) . Given our data, specific inhibition of P 4 s may have therapeutic potential; thus studies are needed to characterize the distribution of properdin forms in inflammatory microenvironments and to develop novel reagents that specifically inhibit each form. Inhibition of endogenous properdin in TRAPstimulated whole blood with mAbs 3A3E1 and 6E11A4 limited PGA formation (Fig. 2A, 2B ). This effect correlated with an ability to inhibit C3 fragment deposition on granulocytes (Fig. 2C,  2D) . Investigation into the mechanisms of complement activation at the platelet/granulocyte interface revealed roles for both the AP and CP (Figs. 3, 4) . Properdin is essential for AP activation on platelets and neutrophils (31, 32) (Fig. 8C, 8D, model) , and platelets also activate the CP on or near their surface (Fig. 8A) (36, 51, 53) . CP activity in the vicinity of the platelet or granulocyte surface could lead to the deposition of C3b on these cells, serving as a site for formation of the AP C3 convertase (C3bBb), which properdin would stabilize, enhancing AP activity (Fig. 8B) . Regardless of the activation mechanism, the generation of C5a is critical for PGA formation in TRAP-stimulated whole blood, resulting in enhanced CR3 expression to form stable aggregates (Figs. 4-6, 8E ). Inhibition of properdin was as effective at controlling PGA formation as specific inhibition of the C5a-C5aR1 axis (Fig. 4A, 4B ), reflecting the ability of the inhibitory properdin Abs to significantly reduce C5a generation at the platelet/granulocyte interface (Fig. 5B) . The only complement-specific inhibitor currently in the clinic is an anti-C5 mAb; however direct inhibition of FIGURE 8 . Model for the mechanism of properdin's effects on PGA formation. (A) Activated platelets initially tether to granulocytes via P-selectin/ PSGL-1 interactions, where they activate the CP on their surface and/or secrete chondroitin sulfate, a known activator of the CP. (B) Properdin-enhanced AP activity amplifies CP activity initiated by platelets, leading to the deposition of C3b on the granulocyte surface. The AP can then use deposited C3b to amplify its activity directly on the granulocyte surface. The AP also activates spontaneously on (C) neutrophils and activated platelets, and (D) AP activity is enhanced by high levels of properdin oligomers (P 2 , P 3 , and especially P 4 ), secreted from neutrophils. (E) Properdin-enhanced AP activity ultimately leads to increased levels of C5a that binds to C5aR1 on neutrophils to enhance CR3 expression. (F) FH regulates AP/properdin-mediated PGA formation.
C5 in clinical trials for myocardial infarction and coronary artery bypass surgery, two conditions associated with increased PGA formation (66, 67) , had disappointing results (68, 69) . Inhibition of properdin significantly reduces AP activity (C3 fragment deposition [ Fig. 2C , 2D] and C5a generation [ Fig. 5B]) at the platelet/granulocyte interface. Patients treated with properdin inhibitors could be effectively protected from neisserial infections (the main consequence of properdin deficiency) with the available tetravalent meningococcal vaccine (70) . Therefore, properdin inhibitors alone or combined with C5aR1 antagonists may be an option to prevent complement-mediated enhancement of PGA formation in vascular diseases, although the therapeutic window for effects of these antagonists remains to be determined experimentally and would likely vary based on the disease context.
Host cells are normally protected from autologous AP complement activation by various redundant membrane-bound (CD55, CD46, CD59, CD35, CRIg) and fluid-phase (Factors H and I) complement regulatory proteins (25, 27) . Addition of the FH competitive inhibitor rH19-20 to whole blood significantly increased TRAP-mediated PGA formation, as well as C3 fragment deposition and CD11b expression (in at least three of six donors) on granulocytes (Figs. 7, 8F ), even though membrane-bound complement regulators are present. The inconsistency in the statistical effects of the reagents on CD11b expression may be a reflection of the sensitivity of our assay, differences in the basal activation state of neutrophils from different donors, or other undetermined sources of interindividual variation, such as noncomplement-mediated factors that govern CD11b upregulation. RH19-20-mediated increases in PGA formation and C3 fragment deposition were consistently abolished by 3A3E1 and 6E11A4 (Figs. 7, 8F ). This indicates that FH is essential for controlling properdin-mediated complement activity, and that properdin has a critical role in enhancing complement activity when FH regulation is absent. These data may also be relevant in aHUS-mediated thromboinflammation mechanisms.
Our study elucidated a critical role for properdin in enhancing PGA formation in whole blood stimulated with TRAP, but platelets can be activated by other agonists (1) . Additional studies have demonstrated PGA formation upon activation with LPS and Shiga toxin (50, 71) , shear stress (72) , and conditions that simulate coronary artery bypass (67, 73) . The extent of complement activation on platelets varies depending on the agonist (31, 51, 74, 75) ; thus the role of properdin in PGA formation may vary based on the agonist used. Because the AP amplifies complement activity initiated by all complement pathways, properdin will likely have a critical role in any effect that depends on complement activation. Collectively, our data implicate properdin as having a key role in enhancing complement activity at the platelet/granulocyte interface, and inhibition of properdin has therapeutic potential to limit thromboinflammation, through limiting PGA formation, even in the absence of FH cell surface protection, such as that which occurs in patients with aHUS.
